MMP1 and ovarian carcinoma: A phase I study of Marimastat (MMP-1, 2, 7, 9 and 14 inhibitor) plus carboplatin was performed in patients with ovarian cancer who previously responded to a platinum-based regimen, and the drug was tolerated well (Thomas, H 1997).